{"id":19164,"date":"2023-03-24T09:41:34","date_gmt":"2023-03-24T09:41:34","guid":{"rendered":"https:\/\/clinlabint.com\/?p=19164"},"modified":"2023-03-24T09:41:34","modified_gmt":"2023-03-24T09:41:34","slug":"who-warns-time-running-out-to-bring-new-antibiotics-to-market","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/who-warns-time-running-out-to-bring-new-antibiotics-to-market\/","title":{"rendered":"WHO warns time running out to bring new antibiotics to market"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

WHO warns time running out to bring new antibiotics to market<\/h1>\/ in E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

A review from WHO on the number of new antibiotics currently in the pipeline shows that just 12 new antibiotics have entered the market in the five years from 2017-21. And there are far too few (just 27) under development in clinical trials against pathogens considered critical by WHO such as Acinetobacter baumannii and Pseudomonas aeruginosa. Of these 27, only six are considered \u2018innovative\u2019 enough to be capable of overcoming antibiotic resistance using WHO criteria with only two of those six targeting highly-drug resistant forms of these microbes.<\/strong><\/p>\n

<\/p>\n

This update on the state of the antibiotic landscape is being presented to a special online session of the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2023, Copenhagen, 15-18 April) and is delivered by Dr Valeria Gigante, Team Lead in WHO\u2019s Antimicrobial Resistance Division, Geneva, Switzerland.<\/p>\n<\/div><\/section>
\n

<\/span><\/span><\/div>
\n
\"\"<\/div><\/div><\/div>
\n

” The rapid increase of multidrug-resistant infections worldwide is concerning. Time is running out for us to bring new antibiotics to market and combat this urgent threat to public health. Without immediate action, we risk returning <\/em>to a pre-antibiotic era where common infections become deadly.”<\/em>
\nDr Valeria Gigante<\/em><\/p>\n<\/div><\/section>
\n

<\/span><\/span><\/div>
\n

\u201cIn the five years covered by this report, we have had just 12 antibiotics approved, with only one of these \u2013 Cefiderocol \u2013 able to target all the pathogens deemed critical by WHO,\u201d explains Dr Gigante. \u201cAnd there are only 27 more currently under development in phase 1 to 3 clinical trials, with little innovation. Only four of the 27 have new mechanisms of action, and most are not new drug classes, but evolution of existing classes.\u201d<\/p>\n

Currently, one antibiotic, Solithroymcin \u2013 to be used to treat community acquired pneumonia and other infections \u2013 is at the \u2018new drug application\u2019 stage (passed through clinical trials and awaiting market authorisation) and a further seven products are in phase 3 trials having their efficacy assessed. Dr Gigante explains, that, since failures are possible even in phase 3 trials, it is difficult to predict if and when a market authorisation will be granted for these drugs.<\/p>\n

According to recent estimates almost 5 million deaths are already associated each year due to antimicrobial resistance (AMR). However, the true burden of resistance could be even greater. Furthermore, AMR disproportionately affects poor individuals who have little access to second line, more expensive antibiotics that could work when first-line drugs fail.<\/p>\n

Antimicrobials are not as lucrative a prospect as other treatments for pharmaceutical companies, because they are mostly short-term treatments and antibiotic stewardship programmes are aimed at conserving or \u2018saving\u2019 any such new drugs until they are desperately needed. And they are just as likely to fail during the research and development process as any other drug for other conditions, yet offer a fraction of the revenue returns compared with, for example, cancer and cardiology drugs. As a result of these and other factors, the research and development process for new antibiotics is challenging and poorly funded. The last novel antibiotic class was discovered in the 1980s, and the first antibiotic from this class, daptomycin, reached the market in 2003.<\/p>\n

Silent pandemic of antibiotic resistance<\/h4>\n

Resistance to antimicrobials develops because of overuse and improper use, such as people not completing their full course of antibiotics or because of the wrong antibiotic being prescribed \u2013 or, in some countries, antibiotics being used widely without prescriptions. The global trend of inappropriate use of antibiotics is demonstrated by the time it takes for resistance to develop to new antibiotics \u2013 for antibiotics launched between 1930 and 1950 the average time to develop resistance was 11 years; for antibiotics launched between the 1970 to 2000 it was just 2-3 years.<\/p>\n

This silent pandemic of antibiotic resistance continues to grow worldwide. Experts repeatedly warn of a \u2018doomsday scenario\u2019 in which routine medical procedures \u2013 for example antibiotic prophylaxis in cancer or other disease care \u2013 would no longer be effective, and untold numbers of people could die
\nfrom what were previously simple, treatable infections.<\/p>\n

One example of a drug-resistance mechanism experts are worried about is New Delhi metallobeta-lactamase 1 (NDM-1). Bacteria which contain the gene to produce this enzyme can break down (and are therefore resistant to) a wide-range of carbapenem antibiotics \u2013 considered part of the last line of defence in antibiotic treatments where other antimicrobials have failed. The most common bacteria that make this enzyme are Escherichia coli and Klebsiella pneumoniae, but the gene for NDM-1 can spread from one strain of bacteria to another. Prevalence of NDM-1 containing bacteria continues to grow worldwide.<\/p>\n

Dr Gigante says: \u201cThere is a major gap regarding products addressing multi-drug resistant (MDR) pathogens such as Acinetobacter baumannii and Pseudomonas aeruginosa (just one agent authorised against all the critical pathogens and few in the pipeline). Very few agents target metallo-\u03b2-lactamases, which continue to grow in prevalence. Few new innovative antibiotics are expected in the coming years. We have no silver bullets.\u201d<\/p>\n

She adds: \u201cThe rapid increase of multidrug-resistant infections worldwide is concerning. Time is running out for us to bring new antibiotics to market and combat this urgent threat to public health. Without immediate action, we risk returning to a pre-antibiotic era where common infections become deadly.\u201d<\/p>\n

She concludes: \u201cWhile we face significant challenges in the fight against antimicrobial resistance, research and development efforts are underway to discover and develop new and hopefully innovative antimicrobial agents, and we have seen promising results in recent years. With increased investment and collabo-
\nration across sectors, we can make progress in the fight against antimicrobial resistance and ensure that patients have an equitable and global access to effective treatments for drug-resistant bacterial infections.\u201d<\/p>\n<\/div><\/section>
\n

\n